Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Validation Of The Ebmt Risk Score In Chronic Myeloid Leukemia In Brazil And Allogeneic Transplant Outcome.
Author: De Souza, Carmino Antonio
Vigorito, Afonso Celso
Ruiz, Milton Artur
Nucci, Márcio
Dulley, Frederico Luiz
Funcke, Vaneusa
Tabak, Daniel
Azevedo, Alexandre Mello
Byington, Rita
Macedo, Maria Cristina
Saboya, Rosaura
Penteado Aranha, Francisco José
Oliveira, Gislaine Barbosa
Zulli, Roberto
Martins Miranda, Eliana Cristina
Azevedo, Wellington Moraes
Lodi, Fernanda Maria
Voltarelli, Júlio Cesar
Simões, Belinda Pinto
Colturato, Vergílio
De Souza, Mair Pedro
Silla, Lúcia
Bittencourt, Henrique
Piron-Ruiz, Lilian
Maiolino, Angelo
Gratwohl, Alois
Pasquini, Ricardo
Abstract: The management of chronic myeloid leukemia (CML) has changed radically since the introduction of imatinib therapy. The decision of whether to offer a patient a hematopoietic stem cell transplant (HSCT) must be based on the probability of success of the procedure. The aim of this retrospective analysis of 1,084 CML patients who received an allogeneic HSCT in 10 Brazilian Centers between February 1983 and March 2003 was to validate the EBMT risk score. The study population comprised 647 (60%) males and 437 (40%) females, with a median age of 32 years old (range 1 - 59); 898 (83%) were in chronic phase, 146 (13%) were in accelerated phase and 40 (4%) were in blast crisis; 151 (14%) were younger than 20 years old, 620 (57%) were between 20 and 40 and 313 (29%) were older than 40; 1,025 (94%) received an HLA fully matched sibling transplant and only 59 (6%) received an unrelated transplant. In 283 cases (26%) a male recipient received a graft from a female donor. The interval from diagnosis to transplantation was less than 12 months in 223 (21%) cases and greater in 861 (79%). The overall survival, disease-free survival, transplant-related mortality and relapse incidence were 49%, 50%, 45% and 25%, respectively. Of the 1084 patients, 179 (17%) had a risk score of 0 or 1, 397 (37%) had a score of 2, 345 (32%) had a score of 3, 135 (12%) had a score of 4 and 28 (2%) a score of 5 or 6. The overall survival (OS) rate in patients with risk scores 0-1 and 2 was similar (58% and 55%, respectively) but significantly better than that in patients with scores 3 or more (score 3 - 44%, 4 - 36 % and 5-6 - 27%, respectively) pp<0.001). Disease-free survival (DFS) and transplant related mortality (TRM) in a patients with a score of 3 or more were 46% and 49%, respectively and the relapse rate beyond score 5-6 was 77%. Disease status had a negative impact on all outcomes (OS, DFS, TRM, and relapse). The OS rate for male recipients of a graft from a female donor was 40% compared to 52% among the other donor-recipient pairs (p=0.004). DFS and TRM were significant for disease phase and female donor-male recipient (p<0.001 and p<0.003, respectively). In our experience, age and interval between diagnosis and transplant did influence OS, DFS, TRM, and relapse rate. Our results validate the EBMT risk score in the context of a developing country and confirm its usefulness for making point decisions in the imatinib era.
Subject: Adolescent
Child, Preschool
Disease-free Survival
Hematopoietic Stem Cell Transplantation
Leukemia, Myelogenous, Chronic, Bcr-abl Positive
Middle Aged
Retrospective Studies
Sex Factors
Transplantation, Homologous
Treatment Outcome
Citation: Haematologica. v. 90, n. 2, p. 232-7, 2005-Feb.
Rights: aberto
Date Issue: 2005
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_15710577.pdf176.67 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.